Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors

Autor:	Siqing Fu, J. Gabrielle Granda, Sarina Anne Piha-Paul, Filip Janku, Manfred B. Klevesath, Gerald S. Falchook, Andreas Johne, David S. Hong, Razelle Kurzrock, Hesham M. Amin, Friedhelm Bladt, Hongxia Zheng, Karola Köhler
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry First in human c-Met inhibitor Internal medicine MSC2156119J medicine Clinical endpoint In patient Tumor growth business
Zdroj:	Journal of Clinical Oncology. 32:2521-2521
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.2521
Popis:	2521^ Background: MSC2156119J, a selective c-Met inhibitor, suppresses tumor growth in preclinical models. Methods: Primary endpoint of this dose-escalation study (3+3 design; NCT01014936): to asse...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f4b3c0163bf3a51f897420d66ae5e77b https://doi.org/10.1200/jco.2014.32.15_suppl.2521 Zobrazit plný text záznamu